-
Product Insights
NewStimulator Of Interferon Genes Protein – Drugs In Development, 2024
The Stimulator Of Interferon Genes Protein pipeline drugs market research report outlays comprehensive information on the Stimulator Of Interferon Genes Protein targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Immunology, Infectious Disease, and Central Nervous System which include indications of Solid Tumor, Unspecified Cancer, Inflammation, Autoimmune Disorders, Coronavirus Disease 2019 (COVID-19), Hepatitis B, Parkinson's Disease, and...
-
Track & Monitor
NewCell & gene therapy in pharma: lentiviral vectors
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the pharma industry’s lentiviral vectors segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge.
-
Product Insights
NewLymphocyte Activation Gene 3 Protein – Drugs In Development, 2024
The Lymphocyte Activation Gene 3 Protein pipeline drugs market research report outlays comprehensive information on the Lymphocyte Activation Gene 3 Protein targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Central Nervous System, Immunology, and Undisclosed which include indications of Solid Tumor, Non-Small Cell Lung Cancer, Central Nervous System, Multiple Sclerosis, Autoimmune Disorders, Rheumatoid Arthritis, and Unspecified....
-
Product Insights
NewCalcitonin Gene Related Peptide Type 1 Receptor – Drugs In Development, 2024
The Calcitonin Gene Related Peptide Type 1 Receptor pipeline drugs market research report outlays comprehensive information on the Calcitonin Gene Related Peptide Type 1 Receptor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Central Nervous System, Dermatology, Undisclosed, and Cardiovascular which include indications of Migraine, Cluster Headache Syndrome (Cluster Headache), Diabetic Foot Ulcers, Rosacea, Unspecified, and Resistant...
-
Product Insights
NewNet Present Value Model: Taysha Gene Therapies Inc’s TSHA-102
Empower your strategies with our Net Present Value Model: Taysha Gene Therapies Inc's TSHA-102 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Innovation Ranking
Innovation Ranking – Daan Gene Co Ltd
Daan Gene Co Ltd (Daan Gene) is a provider of molecular diagnostic solutions. The company develops and produces in-vitro diagnostic products. It offers products such as real-time PCR products, gene sequencing machines, real-time PCR instruments, nucleic acid extraction instruments, reverse dot blot products, fish products, immunoassay products and rapid test products. Daan Gene’s products also include food safety products, blood collection tubes, and reference material and control material. It also offers biotechnology transfer services and biotechnology consulting and exchange services....
-
Innovation Ranking
Innovation Ranking – Sio Gene Therapies Inc
Sio Gene Therapies Inc (Sio Gene) is a clinical-stage biopharmaceutical company that develops and commercializes novel medicines. The company develops medicines for the treatment of multiple forms of dementia and related neurological disorders. Sio Gene's pipeline products comprise AXO-Lenti-PD, AXO-AAV-GM1 and AXO-AAV-GM2. The company’s AXO-Lenti-PD is a lentiviral gene therapy that contains three genes that encode the critical enzymes required for endogenous dopamine synthesis. It develops gene therapies for GM1 and GM2 gangliosidosis including Tay-Sachs disease and Sandhoff disease. The...
-
Product Insights
Innovations in Inborn Gene or Chromosome Alterations – Global Pipeline Summary
GlobalData's Medical Devices sector report, "Innovations in Inborn Gene or Chromosome Alterations - Global Pipeline Summary" provides comprehensive information about the Inborn Gene or Chromosome Alterations pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. The Inborn Gene or Chromosome Alterations report provides key information and data related to: Extensive coverage of the Inborn Gene or Chromosome Alterations under development Review details of major pipeline products which include...
-
Product Insights
Innovations in Acquired Gene or Chromosome Alterations – Global Pipeline Summary
GlobalData's Medical Devices sector report, "Innovations in Acquired Gene or Chromosome Alterations - Global Pipeline Summary" provides comprehensive information about the Acquired Gene or Chromosome Alterations pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. The Acquired Gene or Chromosome Alterations report provides key information and data related to: Extensive coverage of the Acquired Gene or Chromosome Alterations under development Review details of major pipeline products which include...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gene Therapy To Target CD19 For Lymphoma in Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy To Target CD19 For Lymphoma in Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gene Therapy To Target CD19 For...